Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets

J Thromb Haemost. 2014 May;12(5):761-72. doi: 10.1111/jth.12550.

Abstract

Background: Familial platelet disorder with a predisposition to acute myelogenous leukemia (FPD/AML) is an inherited platelet disorder caused by a germline RUNX1 mutation and characterized by thrombocytopenia, a platelet function defect, and leukemia predisposition. The mechanisms underlying FPD/AML platelet dysfunction remain incompletely clarified. We aimed to determine the contribution of platelet structural abnormalities and defective activation pathways to the platelet phenotype. In addition, by using a candidate gene approach, we sought to identify potential RUNX1-regulated genes involved in these defects.

Methods: Lumiaggregometry, α-granule and dense granule content and release, platelet ultrastructure, αIIb β3 integrin activation and outside-in signaling were assessed in members of one FPD/AML pedigree. Expression levels of candidate genes were measured and luciferase reporter assays and chromatin immunoprecipitation were performed to study NF-E2 regulation by RUNX1.

Results: A severe decrease in platelet aggregation, defective αIIb β3 integrin activation and combined αδ storage pool deficiency were found. However, whereas the number of dense granules was markedly reduced, α-granule content was heterogeneous. A trend towards decreased platelet spreading was found, and β3 integrin phosphorylation was impaired, reflecting altered outside-in signaling. A decrease in the level of transcription factor p45 NF-E2 was shown in platelet RNA and lysates, and other deregulated genes included RAB27B and MYL9. RUNX1 was shown to bind to the NF-E2 promoter in primary megakaryocytes, and wild-type RUNX1, but not FPD/AML mutants, was able to activate NF-E2 expression.

Conclusions: The FPD/AML platelet function defect represents a complex trait, and RUNX1 orchestrates platelet function by regulating diverse aspects of this process. This study highlights the RUNX1 target NF-E2 as part of the molecular network by which RUNX1 regulates platelet biogenesis and function.

Keywords: FPD/AML; NF-E2 transcription factor; RUNX1 protein; Rab27B protein, human; blood platelet disorder; platelet function tests.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Adult
  • Blood Platelet Disorders / blood*
  • Blood Platelet Disorders / complications*
  • Blood Platelets / cytology*
  • Core Binding Factor Alpha 2 Subunit / metabolism*
  • Family Health
  • Female
  • Gene Expression Profiling
  • Humans
  • Integrin beta3 / metabolism
  • Leukemia, Myeloid, Acute / blood*
  • Leukemia, Myeloid, Acute / complications*
  • Male
  • NF-E2 Transcription Factor, p45 Subunit / metabolism
  • Pedigree
  • Phenotype
  • Phosphorylation
  • Platelet Aggregation
  • Platelet Function Tests
  • Platelet Membrane Glycoprotein IIb / metabolism
  • Signal Transduction
  • Tyrosine / metabolism
  • Young Adult

Substances

  • Core Binding Factor Alpha 2 Subunit
  • Integrin beta3
  • NF-E2 Transcription Factor, p45 Subunit
  • NFE2 protein, human
  • Platelet Membrane Glycoprotein IIb
  • RUNX1 protein, human
  • Tyrosine
  • Adenosine Triphosphate